 |
|
|
REFERENCES
301.
Price HL: A dynamic concept of the distribution
of thiopental in the human body. Anesthesiology 21:40–45, 1960.
302.
Burch P, Stanski D: The role of metabolism and
protein binding in thiopental anesthesia. Anesthesiology 58:146–152, 1983.
303.
Morgan DJ, Blackman GL, Paull JD, Wolf LJ: Pharmacokinetics
and plasma binding of thiopental. II: Studies at cesarean section. Anesthesiology
54:474–480, 1981.
304.
Pandele G, Chaux F, Salvadori C, et al: Thiopental
pharmacokinetics in patients with cirrhosis. Anesthesiology 59:123–126, 1983.
305.
Toner W, Howard PJ, McGowan WA, Dundee JW: Another
look at acute tolerance to thiopentone. Br J Anaesth 52:1005–1008, 1980.
306.
Jung D, Mayersohn M, Perrier D, et al: Thiopental
disposition in lean and obese patients undergoing surgery. Anesthesiology 56:269–274,
1982.
307.
Downie DL, Franks NP, Lieb WR: Effects of thiopental
and its optical isomers on nicotinic acetylcholine receptors. Anesthesiology 93:774–783,
2000.
308.
Tomlin SL, Jenkins A, Lieb WR, Franks NP: Preparation
of barbiturate optical isomers and their effects on GABA(A) receptors. Anesthesiology
90:1714–1722, 1999.
309.
Judge S: Effect of general anaesthetics on synaptic
ion channels. Br J Anaesth 55:191–200, 1983.
310.
Tanelian DL, Kosek P, Mody I, MacIver MB: The
role of the GABAA
receptor/chloride channel complex in anesthesia. Anesthesiology
78:757–776, 1993.
311.
Snyder SH: Drug and neurotransmitter receptors
in the brain. Science 224:22–31, 1984.
312.
Sloan T: Anesthetics and the brain. Anesthesiol
Clin North Am 20:265–292, 2002.
313.
Michenfelder JD, Milde JH, Sundt TM Jr: Cerebral
protection by barbiturate anesthesia. Use after middle cerebral artery occlusion
in Java monkeys. Arch Neurol 33:345–350, 1976.
314.
Michenfelder JD, Theye RA: Cerebral protection
by thiopental during hypoxia. Anesthesiology 39:510–517, 1973.
315.
Michenfelder JD: The interdependency of cerebral
functional and metabolic effects following massive doses of thiopental in the dog.
Anesthesiology 41:231–236, 1974.
316.
Stullken EH Jr, Milde JH, Michenfelder JD, Tinker
JH: The nonlinear responses of cerebral metabolism to low concentrations of halothane,
enflurane, isoflurane, and thiopental. Anesthesiology 46:28–34, 1977.
317.
Baughman VL: Brain protection during neurosurgery.
Anesthesiol Clin North Am 20:315–327, 2002.
318.
Albrecht RF, Miletich DJ, Rosenberg R, Zahed B:
Cerebral blood flow and metabolic changes from induction to onset of anesthesia
with halothane or pentobarbital. Anesthesiology 47:252–256, 1977.
319.
Dundee JW: Alterations in response to somatic
pain associated with anaesthesia. II: The effect of thiopentone and pentobarbitone.
Br J Anaesth 32:407–414, 1960.
320.
Pancrazio JJ, Frazer MJ, Lynch C 3rd: Barbiturate
anesthetics depress the resting K+
conductance of myocardium. J Pharmacol
Exp Ther 265:358–365, 1993.
321.
Brodie BB, Kurz H, Schanker LS: The importance
of dissociation constant and lipid-solubility in influencing the passage of drugs
into the cerebrospinal fluid. J Pharmacol Exp Ther 130:20–25, 1960.
322.
Mark LC, Burns JJ, Campomanes CI, et al: The
passage of thiopental into brain. J Pharmacol Exp Ther 119:35–38, 1957.
323.
Saidman L: Uptake, distribution and elimination
of barbiturates. In Eger E (ed): Anesthetic Uptake
and Action. Baltimore, Williams & Wilkins, 1974.
324.
Stella L, Torri G, Castiglioni CL: The relative
potencies of thiopentone, ketamine, propanidid, alphaxalone and diazepam. A statistical
study in man. Br J Anaesth 51:119–122, 1979.
325.
Way W, Trevor A: Pharmacology of intravenous
nonnarcotic anesthetics. In Miller RD (ed): Anesthesia,
2nd ed. New York, Churchill Livingstone, 1986.
326.
Brodie B, Mark L, Papper E: The fate of thiopental
in man and method for its estimation in biological material. J Pharmacol Exp Ther
98:85, 1950.
327.
Homer TD, Stanski DR: The effect of increasing
age on thiopental disposition and anesthetic requirement. Anesthesiology 62:714–724,
1985.
328.
Sorbo S, Hudson RJ, Loomis JC: The pharmacokinetics
of thiopental in pediatric surgical patients. Anesthesiology 61:666–670, 1984.
329.
Korttila K, Ghoneim MM, Jacobs L, Lakes RS: Evaluation
of instrumented force platform as a test to measure residual effects of anesthetics.
Anesthesiology 55:625–630, 1981.
330.
Reves JG, Vinik R, Hirschfield AM, et al: Midazolam
compared with thiopentone as a hypnotic component in balanced anaesthesia: A randomized,
double-blind study. Can Anaesth Soc J 26:42–49, 1979.
331.
Reves JG, Samuelson PN, Lewis S: Midazolam maleate
induction in patients with ischaemic heart disease: Haemodynamic observations.
Can Anaesth Soc J 26:402–409, 1979.
332.
Todd MM, Drummond JC, U HS: The hemodynamic consequences
of high-dose thiopental anesthesia. Anesth Analg 64:681–687, 1985.
333.
Rodriguez E, Jordan R: Contemporary trends in
pediatric sedation and analgesia. Emerg Med Clin North Am 20:199–222, 2002.
334.
Liu LM, Gaudreault P, Friedman PA, et al: Methohexital
plasma concentrations in children following rectal administration. Anesthesiology
62:567–570, 1985.
335.
Christensen JH, Andreasen F: Individual variation
in response to thiopental. Acta Anaesthesiol Scand 22:303–313, 1978.
336.
Dundee J, Wyant G: Intravenous Anaesthesia, 2nd
ed. Edinburgh, Churchill Livingstone, 1988.
337.
Kaniaris P, Katsilambros N, Castanas E, Theophanidis
C: Relation between glucose tolerance and serum insulin levels in man before and
after thiopental intravenous administration. Anesth Analg 54:718–721, 1975.
338.
Fragen RJ, Shanks CA, Molteni A, Avram MJ: Effects
of etomidate on hormonal responses to surgical stress. Anesthesiology 61:652–656,
1984.
339.
Kawar P, Dundee JW: Frequency of pain on injection
and venous sequelae following the I.V. administration of certain anaesthetics and
sedatives. Br J Anaesth 54:935–939, 1982.
340.
Bonica J: Intravenous anesthetics. In
Bonica JJ, McDonald JS (eds): Principles and Practice of Obstetric Analgesia and
Anesthesia. Philadelphia, FA Davis, 1967.
341.
Reves J, Gelman S: Cardiovascular effects of
intravenous anesthetic drugs. In Covino B, Fozzard
H, Rehder K (eds): Effects of Anesthesia. Bethesda, MD, American Physiological
Society, 1985, p 179.
342.
Tarabadkar S, Kopriva D, Sreenivasan N, et al:
Hemodynamic impact of induction in patients with decreased cardiac reserve. Anesthesiology
53:S43, 1980.
343.
Seltzer J, Gerson J, Allen F: Comparison of the
cardiovascular effects of bolus v. incremental administration of thiopentone. Br
J Anaesth 52:527–530, 1980.
344.
Eckstein JW, Hamilton WK, McCammond JM: The effect
of thiopental on peripheral venous tone. Anesthesiology 22:525–528, 1961.
345.
Kissin I, Motomura S, Aultman DF, Reves JG: Inotropic
and anesthetic potencies of etomidate and thiopental in dogs. Anesth Analg 62:961–965,
1983.
346.
Sonntag H, Hellberg K, Schenk HD, et al: Effects
of thiopental (Trapanal) on coronary blood flow and myocardial metabolism in man.
Acta Anaesthesiol Scand 19:69–78, 1975.
347.
Dundee JW, Moore J: Thiopentone and methohexital:
A comparison as main anesthetic agents for a standard operation. Anaesthesia 16:50–61,
1961.
348.
Gross JB, Zebrowski ME, Carel WD, et al: Time
course of ventilatory depression after thiopental and midazolam in normal subjects
and in patients with chronic obstructive pulmonary disease. Anesthesiology 58:540–544,
1983.
349.
Wyant GM, Dobkin AD, Aasheim GM: Comparison of
seven intravenous anaesthetic agents in man. Br J Anaesth 29:194–209, 1957.
350.
Choi SD, Spaulding BC, Gross JB, Apfelbaum JL:
Comparison of the ventilatory effects of etomidate and methohexital. Anesthesiology
62:442–447, 1985.
351.
Wood M: Intravenous anesthetic agents. In
Wood M, Wood AJJ (eds): Drugs and Anesthesia: Pharmacology for Anesthesiologists.
Baltimore, Williams & Wilkins, 1982.
352.
Greenblatt D, Shader R: Benzodiazepines in Clinical
Practice. New York, Raven Press, 1974.
353.
Randall LO, Schallek W, Heise GA, et al: The
psychosedative properties of methaminodiazepoxide. J Pharmacol Exp Ther 129:163–171,
1960.
354.
Lemere F: Toxic reactions to chlordiazepoxide.
JAMA 174:893, 1960.
355.
Stovner J, Endresen R: Diazepam in intravenous
anesthesia. Lancet 2:1298–1299, 1965.
356.
Walser A, Benjamin L, Flynn T: Quinazolines and
1,4-benzodiazepines. 84. Synthesis and reactions of imidazo (1,5)(1.4)-benzodiazepines.
J Org Chem 43:936, 1978.
357.
McClish A: Diazepam as an intravenous induction
agent for general anaesthesia. Can Anaesth Soc J 13:562–575, 1966.
358.
Stovner J, Endresen R: Intravenous anaesthesia
with diazepam. Acta Anaesthesiol Scand Suppl 24:223–227, 1966.
359.
Reves JG, Fragen RJ, Vinik HR, Greenblatt DJ:
Midazolam: Pharmacology and uses. Anesthesiology 62:310–324, 1985.
360.
Haefely W, Hunkeler W: The story of flumazenil.
Eur J Anaesthesiol Suppl 2:3–13, 1988.
361.
Barnett A, Fiore JW: Acute tolerance to diazepam
in cats and its possible relationship to diazepam metabolism. Eur J Pharmacol 13:239–243,
1971.
362.
Squires RF, Brastrup C: Benzodiazepine receptors
in rat brain. Nature 266:732–734, 1977.
363.
Greenblatt DJ, Shader RI, Abernethy DR: Drug
therapy. Current status of benzodiazepines. N Engl J Med 309:354–358, 1983.
364.
Arendt RM, Greenblatt DJ, deJong RH, et al: In
vitro correlates of benzodiazepine cerebrospinal fluid uptake, pharmacodynamic action
and peripheral distribution. J Pharmacol Exp Ther 227:98–106, 1983.
365.
Elliott HW: Metabolism of lorazepam. Br J Anaesth
48:1017–1023, 1976.
366.
Blitt CD: Clinical pharmacology of lorazepam.
Contemp Anesth Pract 7:135–145, 1983.
367.
Klotz U, Reimann I: Elevation of steady-state
diazepam levels by cimetidine. Clin Pharmacol Ther 30:513–517, 1981.
368.
Kassai A, Toth G, Eichelbaum M, Klotz U: No evidence
of a genetic polymorphism in the oxidative metabolism of midazolam. Clin Pharmacokinet
15:319–325, 1988.
369.
Bertilsson L: Geographical/interracial differences
in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP)
2D6 and 2C19. Clin Pharmacokinet 29:192–209, 1995.
370.
Barr J, Donner A: Optimal intravenous dosing
strategies for sedatives and analgesics in the intensive care unit. Crit Care Clin
11:827–847, 1995.
371.
Mohler H, Richards JG: The benzodiazepine receptor:
A pharmacological control element of brain function. Eur J Anaesthesiol Suppl 2:15–24,
1988.
372.
Amrein R, Hetzel W: Pharmacology of Dormicum
(midazolam) and Anexate (flumazenil). Acta Anaesthesiol Scand Suppl 92:6–15,
discussion 47, 1990.
373.
Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine
pharmacology. J Pharmacol Exp Ther 300:2–8, 2002.
374.
Amrein R, Hetzel W, Hartmann D, Lorscheid T:
Clinical pharmacology of flumazenil. Eur J Anaesthesiol Suppl 2:65–80, 1988.
375.
Mendelson WB: Neuropharmacology of sleep induction
by benzodiazepines. Crit Rev Neurobiol 6:221–232, 1992.
376.
Strange PG: D1/D2 dopamine receptor interaction
at the biochemical level. Trends Pharmacol Sci 12:48–49, 1991.
377.
Haefely W: The preclinical pharmacology of flumazenil.
Eur J Anaesthesiol Suppl 2:25–36, 1988.
378.
Miller LG: Chronic benzodiazepine administration:
From the patient to the gene. J Clin Pharmacol 31:492–495, 1991.
379.
Breimer LT, Burm AG, Danhof M, et al: Pharmacokinetic-pharmacodynamic
modelling of the interaction between flumazenil and midazolam in volunteers by aperiodic
EEG analysis. Clin Pharmacokinet 20:497–508, 1991.
380.
Persson MP, Nilsson A, Hartvig P: Relation of
sedation and amnesia to plasma concentrations of midazolam in surgical patients.
Clin Pharmacol Ther 43:324–331, 1988.
381.
Forster A, Juge O, Morel D: Effects of midazolam
on cerebral blood flow in human volunteers. Anesthesiology 56:453–455, 1982.
382.
Brown CR, Sarnquist FH, Canup CA, Pedley TA:
Clinical, electroencephalographic, and pharmacokinetic studies of a water-soluble
benzodiazepine, midazolam maleate. Anesthesiology 50:467–470, 1979.
383.
Liu J, Singh H, White PF: Electroencephalogram
bispectral analysis predicts the depth of midazolam-induced sedation. Anesthesiology
84:64–69, 1996.
384.
de Jong RH, Bonin JD: Benzodiazepines protect
mice from local anesthetic convulsions and deaths. Anesth Analg 60:385–389,
1981.
385.
Denaut M, Yernault JC, De Coster A: Double-blind
comparison of the respiratory effects of parenteral lorazepam and diazepam in patients
with chronic obstructive lung disease. Curr Med Res Opin 2:611–615, 1974.
386.
Forster A, Gardaz JP, Suter PM, Gemperle M: Respiratory
depression by midazolam and diazepam. Anesthesiology 53:494–497, 1980.
387.
Sunzel M, Paalzow L, Berggren L, Eriksson I:
Respiratory and cardiovascular effects in relation to plasma levels of midazolam
and diazepam. Br J Clin Pharmacol 25:561–569, 1988.
388.
Brogden RN, Goa KL: Flumazenil. A reappraisal
of its pharmacological properties and therapeutic efficacy as a benzodiazepine antagonist.
Drugs 42:1061–1089, 1991.
389.
Alexander CM, Teller LE, Gross JB: Slow injection
does not prevent midazolam-induced ventilatory depression. Anesth Analg 74:260–264,
1992.
390.
Elliott HW, Nomof N, Navarro G, et al: Central
nervous system and cardiovascular effects of lorazepam in man. Clin Pharmacol Ther
12:468–481, 1971.
391.
Marty J, Gauzit R, Lefevre P, et al: Effects
of diazepam and midazolam on baroreflex control of heart rate and on sympathetic
activity in humans. Anesth Analg 65:113–119, 1986.
392.
Heikkila H, Jalonen J, Arola M, et al: Midazolam
as adjunct to high-dose fentanyl anaesthesia for coronary artery bypass grafting
operation. Acta Anaesthesiol Scand 28:683–689, 1984.
393.
Benson KT, Tomlinson DL, Goto H, Arakawa K: Cardiovascular
effects of lorazepam during sufentanil anesthesia. Anesth Analg 67:996–998,
1988.
394.
Windsor JP, Sherry K, Feneck RO, Sebel PS: Sufentanil
and nitrous oxide anaesthesia for cardiac surgery. Br J Anaesth 61:662–668,
1988.
395.
Reves J, Croughwell N: Valium-fentanyl interaction.
In Reves J, Hall K (eds): Common Problems in Cardiac
Anaesthesia. Chicago, Year Book, 1987, p 356.
396.
Tomichek R, Rosow C, Schneider R: Cardiovascular
effects of diazepam-fentanyl anesthesia in patients with coronary artery disease.
Anesth Analg 61:217, 1982.
397.
Cole SG, Brozinsky S, Isenberg JI: Midazolam,
a new more potent benzodiazepine, compared with diazepam: A randomized, double-blind
study of preendoscopic sedatives. Gastrointest Endosc 29:219–222, 1983.
398.
George KA, Dundee JW: Relative amnesic actions
of diazepam, flunitrazepam and lorazepam in man. Br J Clin Pharmacol 4:45–50,
1977.
399.
Fragen RJ, Caldwell N: Lorazepam premedication:
Lack of recall and relief of anxiety. Anesth Analg 55:792–796, 1976.
400.
McNulty SE, Gratch D, Costello D, et al: The
effect of midazolam and lorazepam on postoperative recovery after cardiac surgery.
Anesth Analg 81:404–407, 1995.
401.
Sanchez-Izquierdo-Riera JA, Caballero-Cubedo RE,
Perez-Vela JL, et al: Propofol versus midazolam: Safety and efficacy for sedating
the severe trauma patient. Anesth Analg 86:1219–1224, 1998.
402.
Vargo JJ, Zuccaro G Jr, Dumot JA, et al: Gastroenterologist-administered
propofol versus meperidine and midazolam for advanced upper endoscopy: A prospective,
randomized trial. Gastroenterology 123:8–16, 2002.
403.
Gauthier RA, Dyck B, Chung F, et al: Respiratory
interaction after spinal anesthesia and sedation with midazolam. Anesthesiology
77:909–914, 1992.
404.
Shapiro BA, Warren J, Egol AB, et al: Practice
parameters for intravenous analgesia and sedation for adult patients in the intensive
care unit: An executive summary. Society of Critical Care Medicine. Crit Care
Med 23:1596–1600, 1995.
405.
Weinbroum AA, Halpern P, Rudick V, et al: Midazolam
versus propofol for long-term sedation in the ICU: A randomized prospective comparison.
Intensive Care Med 23:1258–1263, 1997.
406.
Young C, Knudsen N, Hilton A, Reves JG: Sedation
in the intensive care unit. Crit Care Med 28:854–866, 2000.
407.
Walder B, Elia N, Henzi I, et al: A lack of evidence
of superiority of propofol versus midazolam for sedation in mechanically ventilated
critically ill patients: A qualitative and quantitative systematic review. Anesth
Analg 92:975–983, 2001.
408.
Kain ZN, Hofstadter MB, Mayes LC, et al: Midazolam:
Effects on amnesia and anxiety in children. Anesthesiology 93:676–684, 2000.
409.
Funk W, Jakob W, Riedl T, Taeger K: Oral preanaesthetic
medication for children: Double-blind randomized study of a combination of midazolam
and ketamine vs midazolam or ketamine alone. Br J Anaesth 84:335–340, 2000.
410.
Kanto J, Sjovall S, Vuori A: Effect of different
kinds of premedication on the induction properties of midazolam. Br J Anaesth 54:507–511,
1982.
411.
Gamble JA, Kawar P, Dundee JW, et al: Evaluation
of midazolam as an intravenous induction agent. Anaesthesia 36:868–873, 1981.
412.
Jacobs JR, Reves JG, Marty J, et al: Aging increases
pharmacodynamic sensitivity to the hypnotic effects of midazolam. Anesth Analg 80:143–148,
1995.
413.
Theil DR, Stanley TE 3rd, White WD, et al: Midazolam
and fentanyl continuous infusion anesthesia for cardiac surgery: A comparison of
computer-assisted versus manual infusion systems. J Cardiothorac Vasc Anesth 7:300–306,
1993.
414.
Nilsson A, Persson MP, Hartvig P, Wide L: Effect
of total intravenous anaesthesia with midazolam/alfentanil on the adrenocortical
and hyperglycaemic response to abdominal surgery. Acta Anaesthesiol Scand 32:379–382,
1988.
415.
Crawford ME, Carl P, Andersen RS, Mikkelsen BO:
Comparison between midazolam and thiopentone-based balanced anaesthesia for day-case
surgery. Br J Anaesth 56:165–169, 1984.
416.
Melvin MA, Johnson BH, Quasha AL, Eger EI 3rd:
Induction of anesthesia with midazolam decreases halothane MAC in humans. Anesthesiology
57:238–241, 1982.
417.
File SE, Pellow S: Intrinsic actions of the benzodiazepine
receptor antagonist Ro 15–1788. Psychopharmacology (Berl) 88:1–11, 1986.
418.
Limbird L: Cell Surface Receptors: A Short Course
on Theory and Methods. Boston, Kluwer Academic Publishers, 1986, p 42.
419.
Lauven PM, Schwilden H, Stoeckel H, Greenblatt
DJ: The effects of a benzodiazepine antagonist Ro 15–1788 in the presence
of stable concentrations of midazolam. Anesthesiology 63:61–64, 1985.
420.
Cumin R, Bonetti EP, Scherchlicht R, Haefely WE:
Use of the specific benzodiazepine antagonist, Ro 15–1788, in studies of physiological
dependence on benzodiazepines. Experientia 38:833–834, 1982.
421.
Hunkeler W: Preclinical research findings with
flumazenil (Ro15–1788, Anexate): Chemistry. Eur J Anaesthesiol Suppl 2:37,
1988.
422.
Klotz U, Kanto J: Pharmacokinetics and clinical
use of flumazenil (Ro 15–1788). Clin Pharmacokinet 14:1–12, 1988.
423.
Klotz U: Drug interactions and clinical pharmacokinetics
of flumazenil. Eur J Anaesthesiol Suppl 2:103–108, 1988.
424.
Breimer LT, Hennis PJ, Burm AG, et al: Pharmacokinetics
and EEG effects of flumazenil in volunteers. Clin Pharmacokinet 20:491–496,
1991.
425.
Kleinberger G, Grimm G, Laggner A, et al: Weaning
patients from mechanical ventilation by benzodiazepine antagonist Ro15–1788.
Lancet 2:268–269, 1985.
426.
Knudsen L, Cold GE, Holdgard HO, et al: Effects
of flumazenil on cerebral blood flow and oxygen consumption after midazolam anaesthesia
for craniotomy. Br J Anaesth 67:277–280, 1991.
427.
Wolf J, Friberg L, Jensen J, et al: The effect
of the benzodiazepine antagonist flumazenil on regional cerebral blood flow in human
volunteers. Acta Anaesthesiol Scand 34:628–631, 1990.
428.
Yokoyama M, Benson KT, Arakawa K, Goto H: Effects
of flumazenil on intravenous lidocaine-induced convulsions and anticonvulsant property
of diazepam in rats. Anesth Analg 75:87–90, 1992.
429.
Forster A, Juge O, Louis M, Nahory A: Effects
of a specific benzodiazepine antagonist (RO 15–1788) on cerebral blood flow.
Anesth Analg 66:309–313, 1987.
430.
Samson Y, Hantraye P, Baron JC, et al: Kinetics
and displacement of [11
C]RO 15–1788, a benzodiazepine antagonist,
studied in human brain in vivo by positron tomography. Eur J Pharmacol 110:247–251,
1985.
431.
Dunton AW, Schwam E, Pitman V, et al: The relationship
between dose and duration of action of intravenous flumazenil in reversing sedation
induced by a continuous infusion of midazolam. Eur J Anaesthesiol Suppl 2:97–102,
1988.
432.
Forster A, Crettenand G, Morel D: Absence of
ventilatory agonist or inverse agonist effects of an overdose of Ro15–1788:
A specific benzodiazepine antagonist. Anesthesiology 67:A144, 1987.
433.
Rouiller M, Forster A, Gemperle M: Assessment
of the efficacy and tolerance of a benzodiazepine antagonist (Ro 15–1788) [in
French]. Ann Fr Anesth Reanim 6:1–6, 1987.
434.
Weinbrum A, Geller E: The respiratory effects
of reversing midazolam sedation with flumazenil in the presence or absence of narcotics.
Acta Anaesthesiol Scand Suppl 92:65–69, discussion 78, 1990.
435.
Duka T, Ackenheil M, Noderer J, et al: Changes
in noradrenaline plasma levels and behavioural responses induced by benzodiazepine
agonists with the benzodiazepine antagonist Ro 15–1788. Psychopharmacology
(Berl) 90:351–357, 1986.
436.
Nilsson A: Autonomic and hormonal responses after
the use of midazolam and flumazenil. Acta Anaesthesiol Scand Suppl 92:51–54,
discussion 78, 1990.
437.
White PF, Shafer A, Boyle WA 3rd, et al: Benzodiazepine
antagonism does not provoke a stress response. Anesthesiology 70:636–639,
1989.
438.
Whitwam JG, Amrein R: Pharmacology of flumazenil.
Acta Anaesthesiol Scand Suppl 108:3–14, 1995.
439.
Ghoneim MM, Dembo JB, Block RI: Time course of
antagonism of sedative and amnesic effects of diazepam by flumazenil. Anesthesiology
70:899–904, 1989.
440.
Greifenstein FE, DeVault M, Yoshitake J, Gajewski
JE: A study of a 1-aryl cyclo hexyl amine for anesthesia. Anesth Analg 37:283–294,
1958.
441.
Johnstone M, Evans V, Baigel S: Sernyl (CI-395)
in clinical anaesthesia. Br J Anaesth 31:433–439, 1959.
442.
Lear E, Suntay R, Pallin I: Cyclohexamine (CI-400):
A new intravenous agent. Anesthesiology 20:330–335, 1959.
443.
Corssen G, Domino EF: Dissociative anesthesia:
Further pharmacologic studies and first clinical experience with the phencyclidine
derivative CI-581. Anesth Analg 45:29–40, 1966.
444.
White PF, Way WL, Trevor AJ: Ketamine—its
pharmacology and therapeutic uses. Anesthesiology 56:119–136, 1982.
445.
Cohen ML, Trevor AJ: On the cerebral accumulation
of ketamine and the relationship between metabolism of the drug and its pharmacological
effects. J Pharmacol Exp Ther 189:351–358, 1974.
446.
Chang T, Glazko AJ: Biotransformation and disposition
of ketamine. Int Anesthesiol Clin 12:157–177, 1974.
447.
Cheng G: The pharmacology of ketamine. In
Ketamine. Berlin, Springer-Verlag, 1969, p 1.
448.
White PF, Johnston RR, Pudwill CR: Interaction
of ketamine and halothane in rats. Anesthesiology 42:179–186, 1975.
449.
Cohen MG, Chan SL, Bhargava HN, Trevor AJ: Inhibition
of mammalian brain acetylcholinesterase by ketamine. Biochem Pharmacol 23:1647–1652,
1974.
450.
Grant IS, Nimmo WS, Clements JA: Pharmacokinetics
and analgesic effects of i.m. and oral ketamine. Br J Anaesth 53:805–810,
1981.
